SCHEMBL7175133

SCHEMBL7175133

CC1Nc2cc(Cl)ccc2NC1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.59
CREBBP Q92793 1/20 0.59
TSHR P16473 1/20 0.45
PGR P06401 2/20 0.44
BRD4 O60885 1/20 0.44
AHR P35869 2/20 0.43
CMA1 P23946 1/20 0.43
GSK3B P49841 1/20 0.42
CHEK1 O14757 1/20 0.42
POLB P06746 1/20 0.42
PTPN1 P18031 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CES1 P23141 2/20 0.41
TGM2 P21980 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170205 1.00 BRPF1 (0.59) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL7171052 1.00 BRPF1 (0.59) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL6541516 0.88 BRPF1 (0.54) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL7485845 0.81 TGM2 (0.53) BRPF1CREBBPTSHRPGRCHEK1
SCHEMBL6540662 0.79 BRPF1 (0.59) BRPF1CREBBPTSHRBRD4AHR
SCHEMBL4863718 0.79 BRPF1 (0.59) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL16120451 0.79 BRPF1 (0.59) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL15823711 0.79 BRPF1 (0.59) BRPF1CREBBPTSHRBRD4AHR
SCHEMBL7672651 0.76 CREBBP (0.51) BRPF1CREBBPTSHRPGRBRD4
SCHEMBL7668762 0.75 CREBBP (1.00) BRPF1CREBBPTSHRBRD4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0657166-B1 Combination containing a quinoxaline and a nucleoside AVENTIS PHARMA GMBH (DE) 2003-04-09 EP disclosed
US-6369057-B1 VIRICIDES, IN PARTICULAR AGAINST RETROVIRUSES, HUMAN IMMUNODEFICIENCY VIRUS (HIV) AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
EP-0509398-B1 Quinoxalines, process for their preparation and their use AVENTIS PHARMA GMBH (DE) 2001-09-19 EP disclosed
EP-0657166-A1 Combination containing a quinoxaline and a nucleoside HOECHST AKTIENGESELLSCHAFT (DE) 1995-06-14 EP disclosed
EP-0509398-A1 Quinoxalines, process for their preparation and their use HOECHST AKTIENGESELLSCHAFT (DE) 1992-10-21 EP disclosed